Chisago City, MN, United States of America

Brice Journot

This inventor holds 1 USPTO granted patent and 2 published patent applications and 2 EPO patents. Top assignee: Envoy Medical Corporation. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Brice Journot. Retrieved from https://idiyas.com/inventor/brice-journot

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Brice Journot: Innovator in Medical Technology

Introduction

Brice Journot is an accomplished inventor based in Chicago, US. He is currently associated with Envoy Medical Corporation, where he contributes to advancements in medical technology. Despite having no patents to his name, his work in the field is noteworthy.

Latest Patents

As of now, Brice Journot holds 1 patents. However, his involvement in innovative projects at Envoy Medical Corporation showcases his commitment to developing new solutions in healthcare.

Career Highlights

Brice has made significant contributions to the medical technology sector through his role at Envoy Medical Corporation. His expertise and dedication to improving patient care are evident in the projects he undertakes.

Collaborations

Due to space constraints, the collaborations section will be omitted.

Conclusion

Brice Journot is a dedicated inventor whose work at Envoy Medical Corporation reflects his passion for medical innovation. His contributions, although not yet recognized through patents, are vital to the advancement of healthcare technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…